MANNKIND CORP 8K

MannKind furnished Q2 2026 earnings and a business update, reporting strong revenue growth but higher losses alongside new FDA approvals, pipeline progress, and a financing transaction to fund a CVR obligation tied to Furoscix ReadyFlow.

MannKind Corporation filed a Form 8-K to furnish its second quarter 2026 financial results and business update, reporting a 43% year-over-year increase in total revenues to $109.4 million driven largely by the addition of Furoscix following the 2025 scPharma acquisition and higher collaboration and royalty revenue from United Therapeutics’ Tyvaso DPI, while also highlighting two new FDA approvals (Afrezza’s pediatric indication and the Furoscix ReadyFlow autoinjector), positive Phase 1b data for its nintedanib DPI (MNKD-201) program, increased R&D and SG&A expenses tied to product development and launches, a $50 million private placement to fund a $45 million CVR payment triggered by the Furoscix ReadyFlow approval, and a shift from prior-year profitability to a net loss of $19.0 million for the quarter and $35.7 million year-to-date.

Filing Facts

CIK

899460

Ticker

MNKD

Form

8K

Source Type

fda

Accession

0001193125-26-335016

Alert Tier

7